FMC Corporation (FMC)
NYSEMaterialsAgricultural InputsSnapshot 2026-10-29
$6.20+30.53%
Close 2026-10-30 · 1-day change
NYSEMaterialsAgricultural InputsSnapshot 2026-10-29
Research Workspace
Put FMC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Reduce debt by about $1 billion: Direct metric needs a verified mapping.
View ThesisRevenue is contracting — down about 22% over the past year.
View GrowthManagement screens weak on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 84% in its worst 12-month stretch.
View RiskFMC’s case rests on new active ingredients driving growth, despite weak financial performance. Revenue fell 80% year over year in Q3 2026, following a 17% decline in Q2. Q3 2026 earnings missed, with non-GAAP EPS of -4.41. FMC trades at 0.2× sales versus a 1.4× peer median; expectations look modest versus our view. Weak cash backing, channel-health pressure, and unsteady management threaten that case. Our model puts the next-quarter miss probability near 31%. Peer multiples imply a price about 65% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. FMC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering FMC (as of Oct 2026).
Based on 10 Wall Street analysts offering 12-month price targets for FMC in the last 4 months.
Continue this research
Compare FMC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| FMC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Fertilizers & Agricultural Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put FMC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Improve channel health and product competitiveness
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $6.20
The last 12 months of price, then the range of analyst 12-month targets from today’s $6.20.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Low 2027 EBITDA outlook and $672M channel actions signal significant channel-health and competitiveness pressure.
A guidance cut and deteriorating visibility materially weaken confidence in FMC’s growth outlook.
Threatens: Manage operating income amidst losses
A 31% decline tied to outlook signals a significant deterioration in operating expectations.
Threatens: Manage operating income amidst losses
Massive earnings downgrade and 33% stock drop signal serious pressure on operating income.
Weak demand and inventory issues impact growth objectives.
Advances: Drive growth of new active ingredients
Regulatory approval could drive growth of new active ingredients.
Threatens: Announce and execute share buyback program
Cuts outlook indicates potential difficulties in executing share buyback.
Advances: Drive growth of new active ingredients
New active ingredient approval supports growth strategy.
